Enzo Biochem (NYSE: ENZ) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $24.43 million.

For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.